Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-12, Stock:LLY, The news for the past five days is as follows:
2018-12-04: NEWS1: Incyte (INCY) Announces Positive Data on Jakafi for GVHD.NEWS2: Ajovy Is a New Growth Driver for Teva Pharmaceutical.NEWS3: 3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?.NEWS4: 3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?.NEWS5: Bayer Is Just the Latest Pharma Giant to Get Back to Basics.NEWS6: 3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?.
2018-12-06: NEWS1: Here's Why Supernus Pharmaceuticals Is Sinking Today.NEWS2: Here's Why Supernus Pharmaceuticals Is Sinking Today.NEWS3: Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?.NEWS4: Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?.NEWS5: Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?.NEWS6: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS7: Four stocks have avoided the market crush to hit new highs.
2018-12-07: NEWS1: Mallinckrodt (MNK) to Separate Generics & Branded Businesses.NEWS2: Mallinckrodt (MNK) to Separate Generics & Branded Businesses.NEWS3: 7 Stocks to Buy to Survive a Bear Market.NEWS4: 7 Stocks to Buy to Survive a Bear Market.NEWS5: Mallinckrodt (MNK) to Separate Generics & Branded Businesses.NEWS6: 7 Stocks to Buy to Survive a Bear Market.
2018-12-10: NEWS1: The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company.NEWS2: The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company.NEWS3: HDV, MO, MMM, LLY: Large Inflows Detected at ETF.NEWS4: HDV, MO, MMM, LLY: Large Inflows Detected at ETF.NEWS5: The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company.
2018-12-11: NEWS1: What Seattle Genetics’ Bottom-Line Trend Indicates.NEWS2: Understanding Seattle Genetics’ Operational Performance.NEWS3: How’s Seattle Genetics Positioned?.NEWS4: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS5: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS6: Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800.NEWS7: AXON Throws In The Towel On Nelotanserin, MNLO On Watch, VYGR Sails Ahead.NEWS8: AXON Throws In The Towel On Nelotanserin, MNLO On Watch, VYGR Sails Ahead.

Answer: Decrease